格隆汇2月27日丨昊海生科(688366.SH)公布2025年度业绩快报，报告期内，公司实现营业收入24.73亿 元，同比减少8.33%；实现归属于母公司所有者的净利润2.51亿元，同比减少40.30%；实现归属于母公 司所有者的扣除非经常性损益的净利润1.60亿元，同比减少57.67%。 报告期内，随着人工晶状体产品国家带量采购进入两年协议期的第二阶段，叠加行业竞争格局愈加激 烈，本公司子公司深圳市新产业眼科新技术有限公司所经营的美国进口Lenstec品牌人工晶状体业务面 临显著经营压力。一方面，2025年国内白内障手术总量较2024年有所下降，市场整体需求回落；另一方 面，市场竞品数量增加，尤其是国产晶体凭借显著的成本和价格优势，对进口品牌产品形成更大的挑 战，Lenstec产品销售单价与销量在2025年度均呈持续下行态势，深圳新产业2025年的营业利润不达预 期。基于上述经营表现，结合2026年上半年将启动人工晶状体产品第二轮国家带量采购的产品降价预 期，基于审慎性原则，公司对深圳新产业商誉计提减值准备约人民币1.4亿元。该减值金额仅为公司财 务初步测试金额，最终商誉减值准备计提金额将由公司聘请的具备相 ...

Core Viewpoint - Jimin Health (603222) expects a net loss of 210 million to 250 million yuan for 2025, which is an increase compared to the previous year's loss of 59.71 million yuan [1] Financial Performance - The company anticipates a non-recurring net loss of 205 million to 245 million yuan for 2025 [1] - The company has recognized an inventory impairment provision of approximately 37 million yuan for its pre-filled catheter flushing devices and safety syringes [1] Legal and Compliance Issues - Due to the case involving the forgery of company seals by He Qinghong and others, the company has confirmed related losses of approximately 38 million yuan [1] Asset Valuation - The performance of Ezhou Second Hospital is expected to decline in 2025, leading the company to recognize a goodwill impairment provision of approximately 20 million yuan [1] - After this provision, the cumulative impairment recognized will be approximately 136 million yuan, with a remaining book value of about 15.14 million yuan [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) is experiencing significant declines in its operational metrics, with projected net losses for 2025 ranging from -285 million to -342 million yuan [1][4]. Financial Performance - The company anticipates a 14% decrease in revenue for 2025 due to reduced sales of its main products [2][4]. - Yibai Pharmaceutical's total assets have decreased from 74.65 billion yuan in Q3 2018 to 38.38 billion yuan in Q3 2025, a reduction of over 36 billion yuan, representing a decline of approximately 49% [3][12]. - The company has reported substantial losses over the past four years, with net profits for 2022, 2023, and 2024 being -438 million, 103 million, and -317 million yuan respectively [5]. Product Issues - The core product, Aidi Injection, has faced production halts due to regulatory investigations regarding non-compliance with production quality standards [2][6]. - The company has not yet announced the resumption of Aidi Injection production, despite completing internal rectifications [7]. Regulatory Challenges - Yibai Pharmaceutical has been subject to administrative penalties and investigations by regulatory authorities, impacting its operational capabilities [6][8]. Cost Structure - The company's sales expenses are significantly higher than its research and development expenses, with sales costs being approximately ten times greater than R&D costs [10][11]. - In the first three quarters of 2025, sales expenses reached 621 million yuan, accounting for about 43% of the total revenue of 1.447 billion yuan [11].

Core Viewpoint - The company reported a revenue increase of 14.77% in 2024, but net profit decreased by 58.23% due to various factors including declining seed gross margins and increased operating expenses [1][5][6]. Financial Performance - In 2024, the company achieved a revenue of 4.709 billion yuan, up from the previous year, primarily driven by increased seed exports and domestic corn seed sales [5][6]. - The sales revenue from rice seeds was 1.858 billion yuan, a year-on-year increase of 5.67%, while corn seed sales reached 589 million yuan, growing by 20.43% [5]. - The fastest growth came from order grain and silage feed, which generated 1.191 billion yuan, marking a 44.22% increase [5]. Profitability Issues - The company reported a net profit of 114 million yuan, down 58.23% from the previous year, resulting in a decrease of 160 million yuan [1][6]. - The decline in net profit was attributed to three main factors: reduced gross margins in seed business, increased R&D and operating expenses, and significant impairment losses [6][7]. Impairment Losses - The total impairment losses for the year amounted to 238 million yuan, which significantly impacted the net profit [6][7]. - Specific impairment losses included 85.6686 million yuan for accounts receivable, 21.6848 million yuan for other receivables, and 80.7006 million yuan for inventory [6][7]. Audit Concerns - The company's financial statements received a qualified opinion from the auditing firm due to two key issues: the existence and accuracy of certain receivables and the valuation of inventory [7][8]. - The first issue involved accounts receivable related to grain sales, where the company could not confirm the existence and accuracy of 32.7759 million yuan in receivables [7][8]. - The second issue pertained to the valuation of inventory, where the company failed to provide sufficient evidence to support its sales forecasts for corn seed inventory [8][9]. Management Response - The company plans to actively pursue the collection of receivables from three grain sales companies and aims to recover the amounts within two years [9]. - For the corn seed inventory, the company intends to implement various measures to ensure sales within the next two years [9].

Group 1 - The company plans not to distribute profits for the year 2024, including no cash dividends or stock bonuses, due to a negative net profit [2][35][38] - The company's consolidated net profit for 2024 is -24,423,133.43 yuan, while the parent company's net profit is 21,570,680.93 yuan [5][36] - The company aims to reserve operating funds to ensure stable operations and liquidity needs for sustainable development [2][38] Group 2 - The company operates in the manufacturing sector, specifically in the specialized equipment manufacturing industry, focusing on sewing machinery [2] - The sewing machinery industry in China has shown recovery, with 275 large enterprises achieving a revenue of 31.611 billion yuan, a year-on-year increase of 19.04% [3] - The garment industry has seen a stable recovery, with a 0.8% increase in industrial added value and a 4.22% increase in garment production in 2024 [3] Group 3 - The automotive industry, a key customer for the company's medium-thick material sewing equipment, has shown positive growth, with production and sales increasing by 3.7% and 4.5% respectively [4] - The company's overseas subsidiary in Germany faced a sluggish market, with the automotive sector's production remaining stable and machinery output declining by approximately 8% [5] - The company has implemented cost control measures and improved cash flow management to mitigate short-term operational losses [6] Group 4 - The company reported a revenue of 4.411 billion yuan for the reporting period, a year-on-year increase of 16.39%, primarily due to the acquisition of an 80% stake in a subsidiary [8] - The net profit attributable to shareholders decreased by 369.16% to -24.423 million yuan, influenced by reduced sales of high-margin products and lower asset disposal gains [8] - The company has maintained its core business of developing, producing, and selling sewing and intelligent manufacturing equipment, with no significant changes in its business model [5]

Core Points - The Supervisory Board of Yinzuo Group Co., Ltd. held its 11th meeting of the 13th session on March 24, 2025, with all three supervisors present, meeting legal and statutory requirements [1] - The meeting approved the 2024 Supervisory Board Work Report, which will be submitted for shareholder review [1] - The meeting also approved the 2024 Internal Control Evaluation Report, which is available on the Shanghai Stock Exchange website [2] - The 2024 Environmental, Social, and Governance (ESG) Report was approved and will also be submitted for shareholder review [2] - The board approved a proposal for goodwill impairment provision, affirming that the decision was legal, compliant, and in the company's best interest [2] - The 2024 Annual Report and its summary were approved, confirming compliance with relevant laws and regulations [3] - A proposal for the company's shareholder return plan for the next three years (2025-2027) was approved for shareholder review [3]